Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Aspirin Use for Heart Disease Prevention May Benefit Those with Coronary Artery Calcium Deposits

By BiotechDaily International staff writers
Posted on 21 May 2014
Print article
Image: Figure A shows the location and angle of the coronary calcium scan image. Figure B is a coronary calcium scan image showing calcifications in a coronary artery (Photo courtesy of the [US] National Heart, Lung, and Blood Institute).
Image: Figure A shows the location and angle of the coronary calcium scan image. Figure B is a coronary calcium scan image showing calcifications in a coronary artery (Photo courtesy of the [US] National Heart, Lung, and Blood Institute).
A recent study found that taking aspirin to prevent heart disease benefits individuals with high coronary artery calcium (CAC) scores but can actually cause damage from bleeding in individuals with low levels of coronary artery calcium.

An individual's CAC score is determined by using computerized tomography (CT) to scan the coronary blood vessels. Calcium deposits show up as bright white spots on the scan.

Investigators at the Minneapolis Heart Institute (MN, USA) monitored 4,229 individuals participating in the Multi-Ethnic Study of Atherosclerosis (MESA) at six centers in the USA. Participants had no known CVD (cardiovascular disease) or diabetes, were not on aspirin therapy, and were followed for approximately seven years.

Results revealed that participants with elevated CAC scores (greater than 100) were two to four times more likely to benefit from aspirin therapy than to be harmed, even if they did not qualify for aspirin use according to current American Heart Association guidelines. Conversely, MESA participants with no calcified plaque (CAC score = zero) were two to four times more likely to be harmed by aspirin use than to benefit.

“We estimate that individuals with significant plaque buildup in the arteries of the heart are much more likely to prevent a heart attack with aspirin use than to suffer a significant bleed,” said first author Dr. Michael D. Miedema, a preventative cardiologist at the Minneapolis Heart Institute. “On the opposite end of the spectrum, if you do not have any calcified plaque, our estimations indicate that use of aspirin would result in more harm than good, even if you have risk factors for heart disease such as high cholesterol or a family history of the disease.”

“A CAC score of zero is associated with a very low risk of having a heart attack. That means individuals with a score of zero may not benefit from preventive medications, such as aspirin as well as the cholesterol-lowering statin medications. Approximately 50% of middle-aged men and women have a CAC score of zero, so there is a potential for this test to personalize the approach to prevention and allow a significant number of patients to avoid preventive medications, but we need further research to verify that routine use of this test is the best option for our patients.”

The study was published in the May 6, 2014, online edition of the journal Circulation: Cardiovascular Quality and Outcomes.

Related Links:

Minneapolis Heart Institute



Print article

Channels

Genomics/Proteomics

view channel
Image: Molecular model of E3 ubiquitin ligase (green), E2 ubiquitin enzyme (orange), \"activated ubiquitin\" (cyan), and \"allosteric ubiquitin\" (blue) (Photo courtesy of Dr. Bernhard Lechtenberg, Sanford Burnham Prebys Medical Discovery Institute).

Researchers Resolve Molecular Structure of Critical Ubiquitin-Binding Enzyme

The molecular structure of a protein complex critically involved in diverse cellular functions such as cell signaling, DNA repair, and mounting anti-inflammatory and immune responses has been elucidated... Read more

Drug Discovery

view channel
Image: The “cellXpress” automated imaging analysis software enables to efficiently and accurately detect cellular responses (reflected in green) to nephrotoxic compounds (Photo courtesy of Agency for Science, Technology and Research (Singapore)).

First High-Throughput Imaging Platform for Predicting Kidney Toxicity of Chemicals

Researchers have developed a high-throughput platform of automated cellular imaging that efficiently and accurately predicts renal toxicity of chemical compounds without animal testing, providing an improved... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.